Search results
Added:
3 years ago
We are witnessing an epidemic global increase in the prevalence of obesity and its clinical consequences (e.g. insulin resistance and diabetes). This epidemic has been potentiated and sustained by the widespread adoption of unhealthy lifestyles in broad swathes of the population and is characterised by a sedentary lifestyle and an imbalance between the type and characteristics of nutrition,…
View more
Added:
3 years ago
Atherogenic dyslipidaemia encompasses a broad variety of lipid phenotypes. While LDL cholesterol is a well-known risk factor for atherosclerotic cardiovascular disease (ASCVD), there are additional atherogenic lipoproteins that may be targeted to further reduce ASCVD risk.
In their comprehensive review, Lorenzatti and Toth emphasise that, even when LDL cholesterol levels are optimised, ASCVD…
View more
Peter P Toth
Research Area(s) / Expertise:
Author
Dyslipidaemia in the Real World
Added:
2 years ago
Article
Added:
3 years ago
Pharmacological regulation of lipid metabolism in patients with dyslipidaemia is undeniably associated with significant reductions in risk of cardiovascular (CV) morbidity and mortality. There are strong clinical trial data to support the use of lipid-lowering therapies in the settings of both primary and secondary prevention. Statins and fibrates are two classes of drug that have demonstrated…
View more
Added:
3 years ago
The Concepts of Metabolic Syndrome and Cardiometabolic Risk
Cardiometabolic risk represents a situation where the possibilities of developing atherosclerotic cardiovascular disease and diabetes are significantly enhanced as a consequence of the presence of insulin resistance and atherogenic dyslipidaemia. Dyslipidaemia is characterised by the presence of low high-density lipoprotein (HDL)…
View more
Added:
3 years ago
Atherosclerotic cardiovascular disease (CVD) is a global epidemic. As life expectancy has increased, chronic degenerative diseases have become a significant healthcare burden, affecting developed and developing countries alike,1 with atherosclerotic disease the leading cause of death according to the WHO.2 The development of effective strategies for the prevention of cardiovascular events at…
View more
Added:
3 years ago
Therapeutic targeting of dyslipidaemia has been one of the major successes in cardiovascular medicine over the last three decades. On the basis of unequivocal evidence from animal models through to both population and genetic studies in humans, there is a clear association between increasing levels of LDL cholesterol (LDL-C) and incident cardiovascular risk.1 This has prompted efforts to develop…
View more
Added:
2 years ago
Added:
3 years ago
Mounting evidence suggests that atherosclerosis begins in early childhood,1,2 possibly already during foetal life.3 This underscores the importance of primary prevention in early life. As many people suffering from atherosclerotic disease lack conventional risk factors (e.g. heredity, dyslipidaemia, smoking, obesity, diabetes and hypertension), interest has gradually increased in research on 'non…
View more
